Allschwil, Switzerland

Marc Iglarz

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Marc Iglarz

Introduction

Marc Iglarz is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of endothelin-related diseases. With a total of three patents to his name, his work has the potential to impact many lives.

Latest Patents

Marc Iglarz's latest patents focus on the compound aprocitentan, a 4-pyrimidinesulfamide derivative. One of his inventions involves the combination of aprocitentan with an SGLT-2 inhibitor for the treatment of endothelin-related diseases. This invention includes pharmaceutical compositions that comprise aprocitentan in combination with the SGLT-2 inhibitor, as well as crystalline forms of aprocitentan. Another patent details the use of aprocitentan in combination with other active ingredients, such as an angiotensin receptor blocker or a calcium channel blocker, for the prophylaxis or treatment of endothelin-related diseases. This also includes pharmaceutical compositions featuring novel crystalline forms of aprocitentan.

Career Highlights

Marc Iglarz is currently associated with Idorsia Pharmaceuticals Ltd., a company known for its innovative approaches in drug development. His work at Idorsia has allowed him to focus on groundbreaking research and the development of new therapeutic solutions.

Collaborations

Throughout his career, Marc has collaborated with esteemed

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…